CARISOPRODOL- carisoprodol tablet

Страна: САЩ

Език: английски

Източник: NLM (National Library of Medicine)

Активна съставка:

CARISOPRODOL (UNII: 21925K482H) (CARISOPRODOL - UNII:21925K482H)

Предлага се от:

NuCare Pharmaceuticals,Inc.

INN (Международно Name):

CARISOPRODOL

Композиция:

CARISOPRODOL 350 mg

Начин на приложение:

ORAL

Вид предписание :

PRESCRIPTION DRUG

Терапевтични показания:

Carisoprodol tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol tablets, USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2) ]. Carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. There are no data on the use of carisoprodol during human pregnancy. Animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. The primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. Retrospective, postmarketing studies do not show a consistent association between maternal use of meprobamate and an increased r

Каталог на резюме:

Carisoprodol Tablets, USP 350 mg unscored round, white tablets, imprinted DAN and 5513 on the other side. NDC 68071-4112-2 Bottles of 20 NDC 68071-4112-3 Bottles of 30 NDC 68071-4112-6 Bottles of 60 NDC 68071-4112-9 Bottles of 90 NDC 68071-4112-1 Bottles of 120 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight container with child-resistant closure.

Статус Оторизация:

Abbreviated New Drug Application

Данни за продукта

CARISOPRODOL- CARISOPRODOL TABLET
NUCARE PHARMACEUTICALS,INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CARISOPRODOL TABLETS SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CARISOPRODOL
TABLETS.
CARISOPRODOL TABLETS, USP FOR ORAL USE, CIV
INITIAL U.S. APPROVAL: 1959
INDICATIONS AND USAGE
Carisoprodol tablets, USP are indicated for the relief of discomfort
associated with acute, painful musculoskeletal conditions
in adults ( 1)
Limitations of Use:
Should only be used for acute treatment periods up to two or three
weeks ( 1)
DOSAGE AND ADMINISTRATION
Recommended dose is 250 mg to 350 mg three times a day and at bedtime.
(2)
DOSAGE FORMS AND STRENGTHS
Tablets: 350 mg ( 3)
CONTRAINDICATIONS
Acute intermittent porphyria ( 4)
Hypersensitivity reactions to a carbamate such as meprobamate ( 4)
WARNINGS AND PRECAUTIONS
Due to sedative properties, may impair ability to perform hazardous
tasks such as driving or operating machinery ( 5.1)
Additive sedative effects when used with other CNS depressants
including alcohol ( 5.1)
Cases of abuse, dependence, and withdrawal ( 5.2, 9.2, 9.3)
Seizures ( 5.3)
ADVERSE REACTIONS
Most common adverse reactions (incidence greater than 2%) are
drowsiness, dizziness, and headache ( 6.1)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ACTAVIS AT
1-800-272-5525 OR FDA AT 1-800-FDA-1088
OR _WWW.FDA.GOV/MEDWATCH_.
DRUG INTERACTIONS
CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic
antidepressants) - additive sedative effects ( 5.1, 7.1)
SEE 17 FOR PATIENT COUNSELING INFORMATION.
REVISED: 3/2016
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Sedation
5.2 Abuse, Dependence, and Withdrawal
5.3 Seizures
6 ADVERSE REACTIONS
6.1 Clinical Studies Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
7.1 CNS Depressants
7.2 CYP2C19 Inhibitors and Inducers
8 USE IN SPECIFIC